Completed

L'apathie Dans La Schizophrénie: Étude Neuropsychologique Et Anatomique

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected at a single point in time - Cross-sectional
Who is being recruted

Mental Disorders+6

+ Nervous System Diseases

+ Neurologic Manifestations

From 20 to 55 Years
See all eligibility criteria
How is the trial designed

Case-Control

Comparing exposures between individuals with and without disease in order to identify potential risk factors.
Observational
Study Start: June 2012
See protocol details

Summary

Principal SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Last updated: January 23, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 2012

Actual date on which the first participant was enrolled.

Apathy, defined as a quantitative reduction of voluntary, goal-directed behaviours (GDB), is a core component of negative symptoms. It has been suggested that the physiopathology of apathy is not a single entity but may be multiple, depending on which specific process or macrofunction is disrupted during completion of GDB. In line with this notion, Levy and Dubois proposed dividing apathic syndromes into three subtypes of disrupted processing: 'a-motivation', 'cognitive inertia', and 'uncoupling'. In schizophrenia, apathy has been associated with executive dysfunction, functional impairment and poor outcome. However, the neurobiological underpinnings of apathy in schizophrenia are poorly understood. Primary objective: confirm that chronic schizophrenic patients are apathic compared to healthy volunteers Secondary objectives: investigate if apathy is related to a particular aspect of the disease (i.e. negative, positive symptomatology and/or deficit form) investigate if apathy correlates with executive dysfunction investigate if apathy is associated with a specific mechanism using an experimental task specially designed to investigate the different mechanism (i.e. 'a-motivation', 'cognitive inertia', and 'uncoupling') investigate if there is a volumetric abnormality affecting the executive system in apathic schizophrenic patients link these eventual volumetric abnormalities to prefrontal cortex-basal ganglia circuits according to a specific subtype of apathy in the apathic schizophrenic group

NCT01689181
Principal SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Last updated: January 23, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

60 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-Control

These studies compare people who have a disease (cases) with those who don't (controls). The goal is to look back at previous exposures or risk factors to identify what might have contributed to the disease.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 20 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeurobehavioral ManifestationsSchizophrenia Spectrum and Other Psychotic DisordersSchizophreniaLethargy

Criteria

Inclusion Criteria (healthy volunteers): Male or Female aged 20 to 55 years old included Under French public assurance system Exclusion Criteria (healthy volunteers): Personal history of neurological disorders Personal history of head injury Alcohol or substance abuse Under psychotropic drug Contraindication for MRI Inclusion Criteria (schizophrenic patients): Male or Female aged 20 to 55 years old included Under French public assurance system diagnosis of schizophrenia according to the DSM-IV R criteria Duration of illness > 5 years clinical stability during the past 2 months (defined as no treatment modification or hospitalisation 2 months prior evaluation) Exclusion Criteria (schizophrenic patients): Schizo-affective disorder Personal history of neurological disorders Personal history of head injury Alcohol or substance abuse Contraindication for MRI

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

INSERM MEDU 945, Centre de Recherche-Institut du Cerveau et de la Moelle (CR-ICM), Hôpital de la Pitié Salpétrière

Paris, FranceOpen INSERM MEDU 945, Centre de Recherche-Institut du Cerveau et de la Moelle (CR-ICM), Hôpital de la Pitié Salpétrière in Google Maps
CompletedOne Study Center